Di Fan | Molecular Imaging in Drug Development | Best Researcher Award

Ms. Di Fan | Molecular Imaging in Drug Development | Best Researcher Award

Capital Medical University | China

AUTHOR PROFILE

Scopus

๐Ÿ“Œ DI FAN, PhD

Associate Researcher
Department of Nuclear Medicine, Beijing Tiantan Hospital, Capital Medical University

๐ŸŽ“ EDUCATION AND EARLY ACADEMIC PURSUITS

Di Fan pursued his Bachelorโ€™s degree at Wuhan University (2006-2010), where he built a strong foundation in biomedical sciences. His passion for advanced medical research led him to Peking University (2010-2015), where he obtained his PhD. During his doctoral studies, he focused on radiopharmaceuticals and molecular imaging, setting the stage for a career dedicated to cutting-edge advancements in nuclear medicine.

๐Ÿฅ PROFESSIONAL ENDEAVORS

Currently serving as an Associate Researcher at the Department of Nuclear Medicine, Beijing Tiantan Hospital, Capital Medical University, Di Fan plays a pivotal role in advancing molecular imaging and targeted cancer therapies. His work bridges the gap between innovative radiopharmaceuticals and their clinical applications, contributing to the early detection and treatment of cancer.

๐Ÿ”ฌ CONTRIBUTIONS AND RESEARCH FOCUS

Dr. Fanโ€™s research is primarily focused on:

  • Radiopharmaceutical Development โ€“ Designing novel radioactive tracers for precise cancer imaging and treatment.
  • Molecular Imaging โ€“ Utilizing advanced PET and SPECT imaging techniques to enhance tumor detection and therapeutic monitoring.
  • Targeted Cancer Therapy โ€“ Developing radiolabeled compounds to selectively attack cancer cells, minimizing damage to healthy tissues.

His work contributes significantly to improving personalized cancer treatment, ensuring higher accuracy in diagnosis and therapy.

๐ŸŒ IMPACT AND INFLUENCE

Dr. Fanโ€™s contributions have been recognized through numerous scientific publications, collaborations with leading medical institutions, and participation in national and international research projects. His expertise in nuclear medicine and molecular imaging has influenced both clinical practices and medical innovations in China and beyond.

๐Ÿ“š ACADEMIC CITES AND RECOGNITION

  • Published extensively in high-impact SCI-indexed journals related to radiopharmaceuticals and cancer imaging.
  • H-index and citations reflect his significant contribution to the field of nuclear medicine.
  • Regularly invited to present at global medical and radiology conferences, sharing insights on novel imaging techniques.

๐Ÿš€ LEGACY AND FUTURE CONTRIBUTIONS

Dr. Fan aims to:
โœ… Develop next-generation radiopharmaceuticals for better cancer detection and treatment.
โœ… Strengthen collaborations between academic and clinical institutions to enhance nuclear medicine applications.
โœ… Advance precision oncology, integrating AI-driven analysis for personalized cancer therapies.

His research will continue shaping the future of molecular imaging and targeted therapies, ensuring breakthroughs in early cancer diagnosis and patient-centered treatments.

๐ŸงฌCONCLUSION

Dr. Di Fan stands at the forefront of nuclear medicine research, making significant strides in radiopharmaceuticals, molecular imaging, and targeted cancer therapy. His dedication to scientific innovation and clinical application has not only enhanced cancer diagnostics and treatment but also paved the way for more effective and personalized medical approaches.

 

๐Ÿ“Š๐Ÿ”ฌNOTABLE PUBLICATION:
    1. Title: Utilisation of the Innovative [18F]-Labelled Radiotracer [18F]-BIBD-071 Within HR+ Breast Cancer Xenograft Mouse Models
      Authors: D., Fan, Di , X., Wang, Xin , X., Ling, Xueyuan , … Z., Wu, Zehui , L., Ai, Lin
      Journal: Pharmaceuticals
      Year: 2025

Dr. Pengchong Wang | Cancer Therapy | Best Researcher Award

Dr. Pengchong Wang | Cancer Therapy | Best Researcher Award

Shaanxi Provincial People’s Hospital | China

AUTHOR PROFILE

Scopus

๐Ÿ’Š WANG PENGCHONG: ACADEMIC PROFILE AND ACHIEVEMENTS ๐ŸŽ“


๐ŸŽ“EARLY ACADEMIC PURSUITS ๐Ÿ“š

Wang Pengchong, the Chief Pharmacist at Shaanxi Provincial People’s Hospital, earned his PhD in Pharmacy from Xi’an Jiaotong University. His academic journey was shaped by a focus on tumor pharmacy and targeted drug delivery systems. His early years were spent delving into the intricacies of pharmaceutical care, particularly in the context of oncology, laying the foundation for his future breakthroughs.

๐Ÿ’ผ PROFESSIONAL ENDEAVORS ๐Ÿฅ

Wang is a dedicated member of the Pharmaceutical Care Committee of the Shaanxi Pharmacological Society. His professional work has revolved around tumor pharmacology, pioneering approaches to targeted cancer treatments. He has played an instrumental role in several major projects, including three general projects funded by the National Natural Science Foundation of China and two key R&D projects in Shaanxi Province. His leadership in high-profile initiatives highlights his influence on pharmaceutical advancements.

๐Ÿ”ฌ CONTRIBUTIONS AND RESEARCH FOCUS ๐ŸŽฏ

Wang Pengchong’s research is centered on targeted drug delivery systems and tumor pharmacy research. His contributions are geared toward improving cancer therapies by focusing on precision medicine, which minimizes side effects and enhances the effectiveness of treatment. His work extends into innovative methods, such as nanotechnology in drug targeting. Wang has led multiple significant projects, including the Shaanxi Province Science and Technology Plan Project, the Xi’an City Science and Technology Plan Project, and the Yaodong Shenzhou Pharmaceutical Research Capacity Building Project.

โœจ IMPACT AND INFLUENCE ๐ŸŒ

Wang’s research has had a profound impact on cancer treatment strategies and pharmaceutical care. His efforts have advanced both the scientific understanding and practical application of cancer drugs, particularly in how they can be precisely targeted to tumor cells while sparing healthy tissues. Through his leadership in government-backed research initiatives, Wang has become a driving force in the field, influencing not just Shaanxi Province but the broader pharmaceutical landscape.

๐Ÿ“Š ACADEMIC CITES ๐Ÿ“„

In the past five years, Wang Pengchong has published more than ten SCI-indexed papers in international journals. His work is widely cited, particularly in oncology and pharmaceutical sciences. His research topics span from cutting-edge drug delivery systems to therapeutic advancements, solidifying his reputation in the global scientific community.

๐ŸŒ LEGACY AND FUTURE CONTRIBUTIONS ๐Ÿ†

Wang Pengchongโ€™s legacy will continue to grow as he contributes to targeted cancer therapies and pharmaceutical innovations. His role in advancing precision medicine ensures that his work will influence the next generation of cancer treatments. By leading critical projects and setting new benchmarks in oncology pharmacy, Wang is shaping the future of drug delivery systems and cancer care. His ongoing commitment to pharmaceutical research guarantees that his contributions will leave a lasting impact on the field.

๐Ÿ“ˆ CONCLUSION ๐ŸŒŸ

Wang Pengchongโ€™s distinguished career as a Chief Pharmacist and researcher has made significant strides in the fields of targeted drug delivery systems and tumor pharmacy. His academic foundation, coupled with leadership in high-impact research projects, has not only advanced cancer treatment but also positioned him as a key contributor to pharmaceutical sciences. With over a decade of impactful publications and successful project leadership, Wangโ€™s research continues to shape the future of oncology treatments, fostering innovations that will benefit patients worldwide. His work embodies a lasting legacy of precision medicine and cutting-edge cancer therapies, ensuring he remains a pivotal figure in pharmaceutical research and development. ๐ŸŒ๐Ÿ”ฌ

 

๐Ÿ“Š๐Ÿ”ฌNOTABLE PUBLICATION:

 

    • Mucoadhesive nanoparticles-based oral drug delivery systems enhance ameliorative effects of low molecular weight heparin on experimental colitis
      • Authors: Yan, Y., Sun, Y., Wang, P., Xing, J., Dong, Y.
      • Journal: Carbohydrate Polymers
      • Year: 2020

     

    • An improved synthesis of water-soluble dual fluorescence emission carbon dots from holly leaves for accurate detection of mercury ions in living cells
      • Authors: Wang, P., Yan, Y., Zhang, Y., Xing, J., Dong, Y.
      • Journal: International Journal of Nanomedicine
      • Year: 2021

     

    • One-pot synthesis of nuclear targeting carbon dots with high photoluminescence
      • Authors: Wang, P., Ji, H., Guo, S., Xing, J., Dong, Y.
      • Journal: Chinese Chemical Letters
      • Year: 2021

     

    • Hyaluronic acid-based M1 macrophage targeting and environmental responsive drug releasing nanoparticle for enhanced treatment of rheumatoid arthritis
      • Authors: Wang, P., Zhang, Y., Lei, H., Xing, J., Dong, Y.
      • Journal: Carbohydrate Polymers
      • Year: 2023

     

    • Multifunctional nanosystems sequentially regulating intratumor Fenton chemistry by remodeling the tumor microenvironment to reinforce chemodynamic therapy
      • Authors: Dong, K., Chen, W., Zhao, Z., Lu, T., Dong, Y.
      • Journal: Biomaterials Advances
      • Year: 2022

Dr. Lei Xia | Theranostics | Best Researcher Award

Dr. Lei Xia | Theranostics | Best Researcher Award

Peking University Cancer Hospital |ย  China

Author Profile

Scopus

Orcid Id

Dr. Xia Lei, PhD ๐Ÿงฌ

Affiliation:
Department of Nuclear Medicine, Peking University Cancer Hospital
Physician, Associate Researcher

Contact Information:
๐Ÿ“ž Phone: 18811177191
โœ‰๏ธ Email: xialei9012288@126.com

Biography:

Dr. Xia Lei, PhD, currently serves as a physician and associate researcher in the Department of Nuclear Medicine at Peking University Cancer Hospital. Dr. Lei graduated from the Medical School of Peking University in 2020. His expertise and research interests lie in the innovative field of nuclear medicine, particularly focusing on the development and clinical application of radiopharmaceutical probes for tumor targeting.

His primary research areas include:

  1. Construction of Tumor-Targeted Multimodal Imaging Molecular Probes ๐Ÿฉป
    • Dr. Lei is dedicated to creating advanced imaging probes that can target tumors with high precision, enhancing the accuracy of tumor detection and diagnosis.
  2. Development and Preliminary Application of Novel Integrated Diagnostic and Therapeutic Probes ๐Ÿงซ
    • He is pioneering the integration of diagnostic and therapeutic functions into single probes, aiming to streamline and improve the effectiveness of cancer treatment.
  3. Preparation and Clinical Translation of Tumor-Targeted Radiopharmaceutical Probes ๐Ÿงช
    • Dr. Lei’s work involves preparing radiopharmaceuticals that specifically target tumors and translating these innovations from the lab to clinical settings to benefit patients.

Principal Investigator in Projects:

Dr. Lei has been the principal investigator for several prestigious projects, showcasing his leadership in research and innovation:

  1. National Natural Science Foundation of China, Young Scientists Fund (NO.82202201) ๐ŸŒŸ
    • RMB 300,000 (January 2023 – December 2025)
  2. Young Talents Support Plan by the China Association for Science and Technology (NO. YESS20220230) ๐ŸŒŸ
    • RMB 600,000 (January 2023 – December 2025)
  3. Beijing Natural Science Foundation, General Program (NO.7242266) ๐ŸŒŸ
    • RMB 200,000 (January 2024 – December 2026)
  4. Peking University Cancer Hospital Science Innovation and Translation Fund ๐ŸŒŸ
    • RMB 140,000 (January 2024 – December 2024)
  5. Medical School of Peking University, Young Scientists Innovation Fund ๐ŸŒŸ
    • RMB 40,000
  6. Internal Fund of Peking University Cancer Hospital ๐ŸŒŸ
    • RMB 80,000
  7. Peking University Cancer Hospital Science Innovation Nurturing Fund ๐ŸŒŸ
    • RMB 100,000

Dr. Lei’s contributions to the field of nuclear medicine are instrumental in advancing the understanding and treatment of cancer, reflecting his commitment to medical innovation and patient care.

 

๐Ÿ“Š๐Ÿ”ฌNotable Publication: